Buprenorphine (Experimental) — Competitive Intelligence Brief

Buprenorphine (Experimental) (Buprenorphine (Experimental)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial mu-opioid receptor agonist. Area: Pain Management; Substance Use Disorder.

marketed Partial mu-opioid receptor agonist Mu-opioid receptor (μ-OR) Pain Management; Substance Use Disorder Small molecule

Target snapshot

Buprenorphine (Experimental) (Buprenorphine (Experimental)) — University of Alabama at Birmingham. Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Buprenorphine (Experimental) TARGET	Buprenorphine (Experimental)	University of Alabama at Birmingham	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Use of buprenorphine with FAO > 30 OME	Use of buprenorphine with FAO > 30 OME	Fox Chase Cancer Center	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine Buccal Film [Belbuca]	Buprenorphine Buccal Film [Belbuca]	Carolinas Pain Institute	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Transmucosal Buprenorphine	Transmucosal Buprenorphine	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine SL	Buprenorphine SL	New York State Psychiatric Institute	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Sublingual Buprenorphine (SLB)	Sublingual Buprenorphine (SLB)	NYU Langone Health	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Immediate Release Sublingual Buprenorphine	Immediate Release Sublingual Buprenorphine	Royal Victoria Hospital, Canada	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Partial mu-opioid receptor agonist class)

1. Indivior Inc. · 3 drugs in this class
2. New York State Psychiatric Institute · 3 drugs in this class
3. Orexo AB · 2 drugs in this class
4. BioDelivery Sciences International · 2 drugs in this class
5. King's College London · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. National Institute on Drug Abuse (NIDA) · 1 drug in this class
10. Purdue Pharma LP · 1 drug in this class